MESO Stock — Mesoblast Limited

Mesoblast Limited (MESO)

Updated October 16, 2026.

MESO is a Stock. Total return is 13279900.0% over the past 20.7 years, 13279128.2 points ahead of SPY at 771.8%.

Mesoblast Limited is an Australian regenerative medicine company developing cell-based therapies using mesenchymal lineage cells to treat conditions including graft versus host disease, heart failure, muscular dystrophy, inflammatory bowel disease, and other serious illnesses; most of its pipeline candidates are in Phase III clinical trials. The company maintains strategic partnerships with pharmaceutical firms including Tasly Pharmaceutical Group, Grünenthal GmbH, and JCR Pharmaceuticals. This is a clinical-stage biotech company with no established distribution history.

MESO performance versus SPY

Price and return data through 2026-10-16.

Total return is 13279900.0% over the past 20.7 years, 13279128.2 points ahead of SPY at 771.8%. Over the past year its total return — price change plus distributions reinvested — is -26.6%. Its deepest 1-year drawdown was 37.1%.

MESO key facts

Asset type

Stock

Asset class

Equity

Distribution frequency

None

Last close

$13.28 (as of 2026-10-16)

Market cap

$1,724,472,780

Average volume

615686.0

Beta

0.859

Payout ratio

0.0%

Forward P/E

454.5455

EPS

$-0.44

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

MESO risks and drawbacks

The deepest 1-year drawdown on record here is 37.1%.

Who may consider MESO — and who may not

It is a weaker fit for investors who need monthly cash flow (MESO does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on MESO

• All tickers starting with M

Tagged: Healthcare, International, Small Caps.

Frequently asked questions